Core Viewpoint - The pharmaceutical sector experienced a significant rebound, with various indices showing notable increases, particularly following the implementation of a new index scheme that focuses solely on core innovative drug companies [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 3.7% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 3.6% [1] - The CSI Innovative Drug Industry Index saw a rise of 2.9% [1] - The CSI Biotechnology Theme Index grew by 2.5% [1] - The CSI 300 Pharmaceutical and Health Index climbed by 2.2% [1] Group 2: Index Changes - The new index scheme for the Hang Seng Hong Kong Stock Connect Innovative Drug Index has officially taken effect, which excludes CXO companies [1] - The revised index will focus exclusively on core innovative drug companies, achieving a "purity" of 100% among the indices tracked by ETFs [1]